Table 1.
Baseline characteristics of patients receiving anti‐interleukin‐12/23 agent (ustekinumab) or TNFi (etanercept and adalimumab)
| Characteristics | Ustekinumab | TNFi |
|---|---|---|
| Number of patients (N = 5468) | 951 | 4517 |
| Age (years; N = 5468) | 45 (35–54) (n = 951) | 44 (35.2–53) (n = 4517) |
| Sex, male (N = 5468) | 590 (62.0) (n = 951) | 2645 (58.6) (n = 4517) |
| Ethnicity, white (N = 5461) | 853 (89.7) (n = 951) | 4157 (92.2) (n = 4510) |
| BMI (kg/m2; N = 4983) | 30.3 (26.2–35.7) (n = 851) | 29.4 (25.9–33.8) (n = 4132) |
| Obese (BMI ≥30 kg/m2) | 441 (51.8) (n = 851) | 1922 (46.5) (n = 4132) |
| Ever smoke (yes/no; N = 4885) | 599 (66.6) (n = 899) | 2541 (63.8) (n = 3986) |
| Disease durations (years; N = 5417) | 19 (11–30) (n = 943) | 20 (12–29) (n = 4474) |
| PASI score (N = 4833) | 14.6 (11.2–19.2) (n = 845) | 14.1 (11.0–19.3) (n = 3988) |
| DLQI (N = 2949) | 18 (12–24) (n = 460) | 18 (13–24) (n = 2489) |
| Comorbidities | ||
| No comorbidities | 315 (33.1) | 1356 (30.0) |
| Psoriatic arthritis | 134 (14.1) | 1035 (22.9) |
| Hypertension | 241 (25.3) | 1103 (24.4) |
| Diabetes mellitus | 98 (10.3) | 357 (7.9) |
| Dyslipidemia | 98 (10.3) | 435 (9.6) |
| Angina | 20 (2.1) | 57 (1.3) |
| Other heart diseases | 23 (2.4) | 80 (1.8) |
| Other comorbidities | 512 (53.8) | 2422 (53.6) |
| Current alcohol drinking ( N = 4899) | 593 (65.7) (n = 903) | 2854 (71.4) (n = 3996) |
| Alcohol units per week in patients consuming alcohol (N = 3382) | 8 (3–15) (n = 584) | 9 (3–16) (n = 2798) |
| Previous treatment of conventional systemic therapies | ||
| Methotrexate | 667 (70.1) | 3124 (69.2) |
| Ciclosporin | 540 (56.8) | 2585 (57.2) |
| Acitretin | 399 (42.0) | 2008 (44.5) |
| Fumaric acid esters | 165 (17.4) | 879 (19.5) |
| Concomitant therapies during drug therapy | ||
| Methotrexate | 120 (12.6) | 909 (20.1) |
| Ciclosporin | 71 (7.5) | 455 (10.1) |
| Acitretin | 28 (2.9) | 163 (3.6) |
| Fumaric acid esters | 13 (1.4) | 79 (1.8) |
| Concomitant therapies during active use of the exposure or window period | ||
| Methotrexate | 121 (12.7) | 946 (20.9) |
| Ciclosporin | 74 (7.8) | 491 (10.9) |
| Acitretin | 29 (3.1) | 179 (4.0) |
| Fumaric acid esters | 13 (1.4) | 87 (1.9) |
Data are n (%) or median (25th percentile‐75th percentile).
BMI, body mass index; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area Severity Index; TNFi, tumour necrosis factor‐α inhibitors.